Pasithea TherapeuticsKTTA
13F holders, Q1 2025 (March 31)8holders +1
3new positions
2sold out
$1.26avg. 13F price*
At the end of Q1 2025, 8 institutions reported holding Pasithea Therapeutics Corp. (KTTA) in their 13F filings, up 1 from Q4 2024. 3 opened new positions and 2 sold out. The largest holders were AdvisorShares Investments LLC ($66K), Citigroup Inc. ($18K) and UBS Group AG ($6K).
- Company
- Pasithea Therapeutics Corp.
- CUSIP
- 70261F202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $89K |
| Exits | 2 | $195K |
All 13F filers, Q4 2024 → Q1 2025: 72,323 shares bought and 70,531 shares sold, net +1,792 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| AdvisorShares Investments LLC | 0.01% | New | 53,547 | $66K |
| Citigroup Inc. | 0.00% | New | 13,706 | $18K |
| UBS Group AG | 0.00% | Reduce -66.3% | 4,337 | $6K |
| Hurley Capital, LLC | 0.00% | New | 3,689 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +73.2% | 3,267 | $4K |
| JPMorgan Chase & Co. | 0.00% | No change | 150 | $195 |
| Bank of America Corp. | 0.00% | No change | 8 | $10 |
| Royal Bank of Canada | 0.00% | No change | 250 | $0 |
"% of holder's portfolio" is KTTA's weight in each manager's 13F, not the share of Pasithea Therapeutics Corp. the manager owns.